Revlimid Cancer Woes Spark FDA Safety Review
The U.S. Food and Drug Administration said Friday it was conducting a safety review of the blood cancer treatment drug Revlimid, citing studies that found patients who use the drug could...To view the full article, register now.
Already a subscriber? Click here to view full article